Drug intelligence / Profile preview

Weissella confusa WIKIM51

Development stage: Unknown
Lead developer: World Institute of Kimchi
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

WCFA19 is a specific strain of the lactic acid bacterium *Weissella confusa* (strain WIKIM51) originally isolated from dandelion kimchi. It is developed as a probiotic or functional food ingredient aimed at reducing body weight and body fat. In a 12-week randomized, double-blind, placebo-controlled clinical trial involving overweight and obese adults, oral supplementation with 500 mg of WCFA19 was shown to significantly decrease body fat mass and body fat percentage. The strain is thought to exert its anti-obesity effects through modulation of the gut microbiota and metabolic regulation, providing a potential non-pharmacological intervention for weight management.

Other names: Weissella confusa WIKIM51

Beyond the preview

Go deeper on Weissella confusa WIKIM51.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weissella confusa WIKIM51.

Explore the full profile